DE2533701A1 - Immunologische diagnoseprodukte - Google Patents
Immunologische diagnoseprodukteInfo
- Publication number
- DE2533701A1 DE2533701A1 DE19752533701 DE2533701A DE2533701A1 DE 2533701 A1 DE2533701 A1 DE 2533701A1 DE 19752533701 DE19752533701 DE 19752533701 DE 2533701 A DE2533701 A DE 2533701A DE 2533701 A1 DE2533701 A1 DE 2533701A1
- Authority
- DE
- Germany
- Prior art keywords
- agglutination
- particles
- protein
- tetanus
- latex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001900 immune effect Effects 0.000 title claims description 43
- 239000012502 diagnostic product Substances 0.000 title claims description 32
- 229920000126 latex Polymers 0.000 claims description 145
- 239000004816 latex Substances 0.000 claims description 143
- 239000002245 particle Substances 0.000 claims description 118
- 239000003153 chemical reaction reagent Substances 0.000 claims description 100
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 82
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 82
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 80
- 238000012360 testing method Methods 0.000 claims description 77
- 230000004520 agglutination Effects 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 239000004793 Polystyrene Substances 0.000 claims description 68
- 229920002223 polystyrene Polymers 0.000 claims description 67
- 229960000814 tetanus toxoid Drugs 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 47
- 206010043376 Tetanus Diseases 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 40
- 210000002966 serum Anatomy 0.000 claims description 39
- 210000002700 urine Anatomy 0.000 claims description 35
- 230000001588 bifunctional effect Effects 0.000 claims description 27
- 150000001718 carbodiimides Chemical class 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 18
- 238000001179 sorption measurement Methods 0.000 claims description 18
- 230000036039 immunity Effects 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000000984 immunochemical effect Effects 0.000 claims description 12
- 230000035935 pregnancy Effects 0.000 claims description 12
- 239000012736 aqueous medium Substances 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000013641 positive control Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- -1 3-dimethylaminopropyl Chemical group 0.000 claims description 4
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- 102000006771 Gonadotropins Human genes 0.000 claims 5
- 108010086677 Gonadotropins Proteins 0.000 claims 5
- 239000002622 gonadotropin Substances 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 60
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000872 buffer Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 18
- 239000003431 cross linking reagent Substances 0.000 description 17
- 239000008363 phosphate buffer Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 229920004890 Triton X-100 Polymers 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 9
- 229960005367 tetanus antitoxin Drugs 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000001147 anti-toxic effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 238000009007 Diagnostic Kit Methods 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 238000009597 pregnancy test Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 229940036116 tetanus immunoglobulin Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012092 latex agglutination test Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LEOJDCQCOZOLTQ-UHFFFAOYSA-N dibutylcarbamothioyl n,n-dibutylcarbamodithioate Chemical compound CCCCN(CCCC)C(=S)SC(=S)N(CCCC)CCCC LEOJDCQCOZOLTQ-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010082612 homocitrate synthase Proteins 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49399274A | 1974-08-01 | 1974-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2533701A1 true DE2533701A1 (de) | 1976-02-12 |
Family
ID=23962555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752533701 Withdrawn DE2533701A1 (de) | 1974-08-01 | 1975-07-28 | Immunologische diagnoseprodukte |
Country Status (10)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138297A1 (en) * | 1983-09-30 | 1985-04-24 | Becton Dickinson and Company | Immuno-agglutination particle suspensions |
| EP0408078A3 (en) * | 1989-07-14 | 1992-01-29 | Boehringer Mannheim Gmbh | Method for the preparation of a solid phase coated with an immunologically active substance |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5819222B2 (ja) * | 1977-06-21 | 1983-04-16 | 森永乳業株式会社 | ステロイド−血清アルブミン複合体感作ラテックス粒子の製造法 |
| JPS6342342Y2 (enrdf_load_stackoverflow) * | 1978-04-20 | 1988-11-07 | ||
| JPS59224565A (ja) * | 1983-04-28 | 1984-12-17 | Morinaga Milk Ind Co Ltd | 抗原検出用試薬 |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| DE3842700A1 (de) * | 1988-12-19 | 1990-06-21 | Boehringer Mannheim Gmbh | Verfahren zur proteinimmobilisierung an einer festphase, so hergestellte protein tragende festphase sowie deren verwendung |
| DE4343479A1 (de) * | 1993-12-21 | 1995-06-22 | Boehringer Mannheim Gmbh | Acylierte Proteinaggregate und deren Verwendung zur Entstörung von Immunoassays |
| FR2743891B1 (fr) * | 1996-01-18 | 1998-04-10 | Immunotech Sa | Procede pour l'identification ou le dosage immunologique d'antigenes polypeptidiques |
| CN102109521A (zh) * | 2010-12-16 | 2011-06-29 | 中国环境科学研究院 | 检测豇豆胰蛋白酶抑制剂的免疫胶乳微球及其制备方法 |
| CN113495139A (zh) * | 2021-07-07 | 2021-10-12 | 上海清芮科技有限公司 | 一种宠物特应性体质的检测方法 |
-
1974
- 1974-10-14 BE BE149519A patent/BE821053A/xx unknown
-
1975
- 1975-01-01 AR AR259590A patent/AR205649A1/es active
- 1975-06-20 CA CA229,753A patent/CA1032470A/en not_active Expired
- 1975-06-23 ZA ZA00754005A patent/ZA754005B/xx unknown
- 1975-07-03 GB GB28140/75A patent/GB1505400A/en not_active Expired
- 1975-07-18 BR BR7504611*A patent/BR7504611A/pt unknown
- 1975-07-28 DE DE19752533701 patent/DE2533701A1/de not_active Withdrawn
- 1975-07-29 FR FR7523684A patent/FR2280352A1/fr not_active Withdrawn
- 1975-07-31 DK DK349075A patent/DK349075A/da unknown
- 1975-08-01 JP JP50093283A patent/JPS5141422A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138297A1 (en) * | 1983-09-30 | 1985-04-24 | Becton Dickinson and Company | Immuno-agglutination particle suspensions |
| EP0408078A3 (en) * | 1989-07-14 | 1992-01-29 | Boehringer Mannheim Gmbh | Method for the preparation of a solid phase coated with an immunologically active substance |
| US5316784A (en) * | 1989-07-14 | 1994-05-31 | Boehringer Mannheim Gmbh | Process for the production of a solid phase matrix coated with an immunologically active substance |
Also Published As
| Publication number | Publication date |
|---|---|
| BR7504611A (pt) | 1976-08-03 |
| BE821053A (fr) | 1975-04-14 |
| DK349075A (da) | 1976-02-02 |
| JPS5141422A (enrdf_load_stackoverflow) | 1976-04-07 |
| AR205649A1 (es) | 1976-05-21 |
| ZA754005B (en) | 1976-05-26 |
| CA1032470A (en) | 1978-06-06 |
| FR2280352A1 (fr) | 1976-02-27 |
| GB1505400A (en) | 1978-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69128618T3 (de) | Vorrichtung und verfahren zur ausführung von immunoassays | |
| DE3882058T2 (de) | Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies. | |
| DE3884979T2 (de) | Agglutinationsimmunotest und Satz zur Bestimmung einer mehrwertigen Immunspezies unter Verwendung einer gepufferten Salzwasch-Lösung. | |
| DE3650513T2 (de) | Verzögerter immunologischer Test in fester Phase | |
| EP0305337B1 (de) | Verfahren zum Nachweis von Antigenen und/oder Antikörpern sowie Testausrüstung zur Durchführung des Verfahrens | |
| CH627281A5 (enrdf_load_stackoverflow) | ||
| DE2164768A1 (de) | Verfahren zum Nachweis und zur Bestimmung von spezifischen Bindeproteinen | |
| DE2836046A1 (de) | Immunologisches bestimmungsverfahren | |
| DE2633877A1 (de) | Verfahren zur immunpruefung auf antigene in fester phase | |
| DE2653032A1 (de) | Radioimmun-nachweisverfahren fuer ein schilddruesenhormon und dafuer geeignetes reagens | |
| DE19649390A1 (de) | Antigenspezifischer IgG-Nachweis | |
| EP0001223A2 (de) | Mit einer Polyhydroxyverbindung beschichteten Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz. | |
| DE69928507T2 (de) | Festphasenverfahren und Testkit zur Antigen- und Antikörperbestimmung in der Blutgruppen-Serologie | |
| DE2604844C3 (de) | Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem Blut | |
| DE2533701A1 (de) | Immunologische diagnoseprodukte | |
| DE3105555C2 (enrdf_load_stackoverflow) | ||
| DE2322562A1 (de) | Verfahren zur bestimmung eines oder mehrerer antigene in einer probe | |
| CH649306A5 (de) | Traegergebundenes immunglobulin-spaltprodukt und seine verwendung fuer immunologische analysenverfahren. | |
| DE3346795A1 (de) | Enzymimmunoassay und entsprechendes diagnostikum | |
| DE3889479T2 (de) | Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung. | |
| EP0379216B1 (de) | Verfahren und Reagenz zur Bestimmung von immunologisch nachweisbaren Substanzen | |
| EP1386160B1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
| DE2850950C3 (de) | Verwendung von nativem oder thermisch modifiziertem Cytochrom c als Stabilisator für ein immunochemisches Meßreagens, immunochemisches Meßreagens sowie Pufferlösung zur Probenverdünnung bei immunchemischen Meßverfahren | |
| DE3836348A1 (de) | Verfahren zur bestimmung von fuer ein antigen klassenspezifischen antikoerpern und dazu geeignetes reagenz | |
| CH645726A5 (de) | Praeparat zur bestimmung von menschlichem immunoglobulin g, verfahren zu seiner herstellung und seine verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OGA | New person/name/address of the applicant | ||
| 8139 | Disposal/non-payment of the annual fee |